-
What biosimilar threat? Roche wins another reprieve as FDA stiff-arms Novartis Rituxan copy
fiercepharma
May 04, 2018
Roche's Rituxan just got another biosim break. Rival drugmaker Novartis said late Wednesday its knockoff version didn't pass muster at the FDA.
-
FDA approves Tafinlar/Mekinist for BRAF V600-mutant melanoma
europeanpharmaceuticalreview
May 03, 2018
The FDA has approved Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutation…
-
Novartis' Car-T Therapy Kymriah receives second FDA approval
worldpharmanews
May 03, 2018
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah? (tisagenlecleucel) suspension for intravenous infusion for its second indication...
-
Novartis' CAR-T therapy gets second FDA approval
pharmatimes
May 03, 2018
The FDA has approved Novartis' CAR-T therapy Kymriah (tisagenlecleucel) for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma ...
-
Watch out, Gilead—Novartis got the FDA nod it needs to steal your CAR-T market
fiercepharma
May 03, 2018
Novartis won a second FDA approval last night for its CAR-T cancer treatment, Kymriah, potentially expanding the market for a product that has disappointed analysts .
-
Novartis app allows ophthalmology patients to report data
pharmatimes
April 27, 2018
Novartis has launched a new app that enables patients taking part in ophthalmic clinical trials to self-report data, which could potentially speed up the development of new therapies.
-
Novartis Joins Innovative Solution Trend for Clinical Trials: Launches FocalView App
biospace
April 26, 2018
The biopharma industry is starting to leverage mobile apps and other digital technologies to improve access to clinical trials.
-
Novartis invests $100 mn to eliminate malaria
europeanpharmaceuticalreview
April 24, 2018
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years…
-
Novartis and Pear to develop substance use digital therapeutics
pharmaphorum
April 24, 2018
Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a deal with its Sandoz division.
-
Novartis appoints John Tsai as Head GDD, CMO
biospectrumasia
April 23, 2018
At Novartis, he will be responsible for advancing the company's industry-leading pipeline of innovative medicines and biosimilars.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
